PTC Therapeutics (FRA:BH3) FCF Margin % : -17.12% (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is PTC Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. PTC Therapeutics's Free Cash Flow for the three months ended in Dec. 2024 was €-34.9 Mil. PTC Therapeutics's Revenue for the three months ended in Dec. 2024 was €203.6 Mil. Therefore, PTC Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was -17.12%.

As of today, PTC Therapeutics's current FCF Yield % is -4.72%.

The historical rank and industry rank for PTC Therapeutics's FCF Margin % or its related term are showing as below:

FRA:BH3' s FCF Margin % Range Over the Past 10 Years
Min: -345.58 Med: -54.72 Max: -16.31
Current: -22.41

During the past 13 years, the highest FCF Margin % of PTC Therapeutics was -16.31%. The lowest was -345.58%. And the median was -54.72%.

FRA:BH3's FCF Margin % is ranked better than
64.6% of 1000 companies
in the Biotechnology industry
Industry Median: -121.695 vs FRA:BH3: -22.41

PTC Therapeutics FCF Margin % Historical Data

The historical data trend for PTC Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PTC Therapeutics FCF Margin % Chart

PTC Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-65.67

-62.51

-72.86

-29.75

-22.55

PTC Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-41.93	3.05	-34.32	-44.60	-17.12

Competitive Comparison of PTC Therapeutics's FCF Margin %

For the Biotechnology subindustry, PTC Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PTC Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PTC Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where PTC Therapeutics's FCF Margin % falls into.

Save Embed

;

Save Embed

;

PTC Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

PTC Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-173.75	/	770.475
	=	-22.55 %

PTC Therapeutics's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-34.859	/	203.579
	=	-17.12 %

PTC Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of PTC Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

PTC Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PTC Therapeutics Inc (FRA:BH3) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

PTCT:USA

Address

500 Warren Corporate Center Drive, Warren, NJ, USA, 07059

Website

https://www.ptcbio.com

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.

PTC Therapeutics Headlines

No Headlines